价格

GE Healthcare AS

ACTIVE

Nycoveien 1, Oslo, 挪威www.gehealthcare.noSubsidiary成立于: 1874-01-01

别名:

gyda

概览

试验阶段分布

阶段

试验数

占比

3 期

100.0%

试验状态分布

已完成

100.0%

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMA

European Medicines Agency

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

NPRA

National Pharmaceutical Regulatory Agency

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

药物批准

近期批准

OMNIPAQUE 350MG/ML SOLUTION FOR INJECTION

SFDA

2026-09-01

OMNIPAQUE 350MG/ML SOLUTION FOR INJECTION

SFDA

2026-09-01

OMNIPAQUE 300MG/ML SOLUTION FOR INJECTION

SFDA

2026-09-01

OMNIPAQUE 300MG/ML SOLUTION FOR INJECTION

SFDA

2026-09-01

MYOVIEW POWDER FOR INJECTION

NPRA

2025-11-28

CLARISCAN 0.5MMOL/ML SOL. FOR INJECTION

OMNIPAQUE 350MG/ML SOLUTION FOR INJECTION

资讯

暂无资讯文章

返回机构列表

GE Healthcare AS

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（1）

AdreView* Myocardial Imaging for Risk Evaluation * A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 25% * LVEF * 35%. ADMIRE-ICD

药物批准

按机构分类的批准

近期批准

资讯